Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study-Reference-Cited by-同舟云学术

Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study

Published:2021-06 Issue:2 Volume:9 Page:96-100
ISSN:2287-8882
Container-title:Prostate International
language:en
Short-container-title:Prostate International

Author:

Matsumoto Takashi,Shiota Masaki^ORCID,Nakamura Motonobu^ORCID,Yokomizo Akira,Tomoda Toshihisa,Sakamoto Naotaka^ORCID,Seki Narihito,Hasegawa Shuji,Yunoki Takakazu^ORCID,Harano Masahiko,Kuroiwa Kentaro,Eto Masatoshi

Publisher

Elsevier BV

Subject

Urology

Reference16 articles.

1. Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy;Shiota;Frontiers in Oncology,2016

2. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer;Shiota;Int J Urol,2016

3. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial;Horgan;J Geriatric Oncology,2014

4. First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry;Droz;Urol Oncol: Seminars and Original Investigations,2016

5. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer;Sweeney;N Engl J Med,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival beyond cabazitaxel for metastatic castration‐resistant prostate cancer;International Journal of Urology;2024-03-05

2. A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways;Prostate International;2022-11

3. Management of prostate cancer in older patients;JPN J CLIN ONCOL;2022

4. Management of prostate cancer in older patients;Japanese Journal of Clinical Oncology;2022-02-25

5. How to Optimally Sequence Available Therapy Lines in Advanced Prostate Cancer;Acta Clinica Croatica;2022